Aquí encontrará nuestros anuncios más recientes, que incluyen asociaciones, lanzamientos de productos y éxitos de pruebas. Lea a continuación para conocer nuestros anuncios más recientes.
ObvioHealth and 1nHealth announce today a joint initiative to smooth the transition to hybrid and decentralized clinical research. The initiative focuses on supporting clinical trials that may be struggling due to suboptimal protocol design, imprecise recruitment strategies, maladapted technology options or ailing site teams. According to clinicaltrials.gov, there are about 1,600 suspended trials at present.
ObvioHealth, a leading global Virtual Research Organization (VRO) delivering end-to-end decentralized clinical trial solutions, announces it has completed the first fully virtual urogynecology study in partnership with trial sponsor, Renovia, Inc. The trial validated the efficacy of Renovia’s leva® Pelvic Health System on women’s incontinence, a health concern that affects 62% of U.S. adult women.
Novotech, a leading biotech specialist CRO in the Asia-Pacific region, and virtual research organization (VRO) partner ObvioHealth have been selected as finalists for the Clinical Partnership of the Year Citeline Award by Informa Pharma Intelligence. ObvioHealth is Novotech’s preferred provider for virtual clinical trials in APAC, while Novotech is ObvioHealth’s preferred CRO in the region for hybrid and virtual trials.
NEW YORK, September 30, 2021 - ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of a first-of-its kind clinical trial in Australia, using a combination of in-home data collection methods that will reduce and in some cases eliminate the need for follow-up visits to clinics.
NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.